Welcome to our dedicated page for Agenus news (Ticker: AGEN), a resource for investors and traders seeking the latest updates and insights on Agenus stock.
Agenus Inc. (NASDAQ: AGEN) generates a steady stream of news centered on its immuno-oncology pipeline, with particular focus on the botensilimab (BOT) and balstilimab (BAL) combination. As a Lexington, Massachusetts-based biological products manufacturer focused on cancer immunotherapy, the company’s updates frequently highlight progress in clinical trials, early-access frameworks and strategic collaborations.
Many recent headlines relate to BOT+BAL’s performance in advanced solid tumors. Agenus reports data from the C-800-01 Phase 1b trial, which evaluates the combination across multiple refractory cancers, and from the global BATTMAN CO.33 Phase 3 trial in microsatellite-stable colorectal cancer conducted with the Canadian Cancer Trials Group and international academic partners. News coverage also includes peer-reviewed publications, such as results in treatment-refractory ovarian cancer, and presentations at major oncology congresses.
Another major theme in Agenus news is patient access. The company has announced that France’s medicines agency authorized a national Autorisation d’Accès Compassionnel (AAC) protocol for BOT+BAL, enabling fully reimbursed hospital-based access for eligible patients with microsatellite-stable metastatic colorectal cancer, certain ovarian cancers and soft-tissue sarcomas. Additional stories describe named-patient and early-access programs in other geographies where regulations allow.
Strategic and corporate developments also feature prominently. Agenus has disclosed a collaboration with Zydus Lifesciences involving the sale of biologics manufacturing facilities in California, an equity investment in Agenus, and an exclusive license for BOT and BAL in India and Sri Lanka, along with the creation of Zylidac Bio LLC to house the acquired U.S. manufacturing assets. Investors following AGEN news can expect updates on clinical milestones, regulatory interactions, early-access expansions, manufacturing partnerships and periodic financial and corporate communications.
Agenus (Nasdaq: AGEN) will release its fourth quarter and full year 2022 financial results on March 14, 2023, before the market opens. The company specializes in immuno-oncology, targeting cancer and infectious diseases. Following the results, Agenus executives will host a conference call and webcast at 8:30 a.m. ET to discuss the financial outcomes and provide a corporate update. Investors can access the call via dial-in numbers or through a live webcast available on the company’s official website. This event is pivotal for stakeholders, as it will outline key financial metrics and future strategies in the competitive biotechnology landscape.
Agenus (Nasdaq: AGEN), a clinical-stage immuno-oncology company, will present updated data on its lead program botensilimab at the Society of Gynecologic Oncology (SGO) 37th Annual Meeting on Women’s Cancer from March 25-28, 2023, in Tampa, FL.
The presentation will focus on the combination of botensilimab with balstilimab in patients with recurrent platinum refractory/resistant ovarian cancer, scheduled for March 27 at 9:18am ET. Botensilimab aims to treat 'cold' tumors, showing promising results in over 300 patients across various cancers. A global Phase 3 trial in microsatellite-stable colorectal cancer is planned for 2023.
Agenus (NASDAQ: AGEN), a clinical-stage immuno-oncology company, announced that Dr. Garo Armen, Chairman and CEO, along with Dr. Steven O’Day, Chief Medical Officer, will present at two upcoming investor conferences. The Guggenheim 5th Annual Oncology Day will feature a fireside chat on February 9, 2023, at 9:35 AM ET, while the SVB Securities Global Biopharma Conference will host a virtual fireside chat on February 16, 2023, at 10:00 AM ET. Interested parties can access live webcasts through the company’s website. Agenus focuses on cancer immunotherapy, leveraging various therapeutic approaches and resources.
Agenus reported promising clinical data from a Phase 1b study of botensilimab combined with balstilimab in treating microsatellite stable colorectal cancer (MSS CRC). In an expanded cohort of 70 heavily pre-treated patients, the overall response rate (ORR) was 23%, while the disease control rate (DCR) was 76%. Remarkably, 69% of responses were ongoing at the data cut-off, and median overall survival has not yet been reached. The company plans to initiate a Phase 3 trial for MSS CRC in 2023, underscoring a commitment to address the significant unmet needs in this patient population.
Agenus (NASDAQ: AGEN), an immuno-oncology firm, announced participation by Chairman and CEO Dr. Garo Armen and Chief Medical Officer Dr. Steven O’Day in a virtual fireside chat at the B Riley Securities’ 2023 Virtual Oncology Conference on January 18th at 11:30 am ET. This event offers insights into Agenus's innovative therapies targeting cancer and infections. Interested participants can register for the webcast at B Riley's website. An archived version will be available later on Agenus's Investor page, providing ongoing updates about the company's developments.
Agenus Inc. (NASDAQ: AGEN) announced it will present expanded data on botensilimab, an anti-CTLA-4, in combination with balstilimab, an anti-PD-1, at the American Society of Clinical Oncology – Gastrointestinal Cancers Symposium (ASCO-GI) from January 19-21, 2023, in San Francisco, CA. The presentation will focus on data from the microsatellite stable colorectal cancer cohort of its Phase 1 study and occurs on January 21, 2023, at 10:00am ET. Abstract details, including the presenting author, will be released on January 17, 2023.
Agenus (Nasdaq: AGEN) reported promising results from its Phase 1 study of botensilimab and balstilimab for advanced sarcoma treatment. The study revealed a 46% overall response rate and a 69% disease control rate in heavily pre-treated patients. Notably, responses were observed in historically resistant sarcoma subtypes, including visceral angiosarcoma. Furthermore, 67% of responses lasted over a year. With a 12-month overall survival rate of 77%, Agenus plans further Phase 2 trials in 2023.
Agenus (NASDAQ: AGEN), a leader in immuno-oncology, will participate in the 5th Annual Evercore ISI HealthCONx Conference. Dr. Garo Armen and Dr. Steven O'Day will join a virtual fireside chat on November 30th at 12:35 PM ET. The conference runs from November 29th to December 1st, including one-on-one investor meetings. Interested attendees can register for the webcast, which will also be archived on Agenus' investor website following the event. Agenus focuses on therapies that harness the immune system to combat cancer and infections.
Agenus (Nasdaq: AGEN) reported promising results from its Phase 1 study of botensilimab and balstilimab for treating treatment-resistant tumors, including MSS-CRC, ovarian, and NSCLC. The response rates ranged from 22% in MSS-CRC to 60% in anti-PD-(L)1 resistant NSCLC. The company has initiated Phase 2 ACTIVATE trials for botensilimab in advanced MSS-CRC and melanoma, with pancreatic cancer trials expected by year-end. The therapy has shown higher efficacy and tolerability compared to existing treatments, marking a significant step forward in immuno-oncology.
Agenus Inc. (NASDAQ: AGEN) provided a corporate update and third-quarter 2022 financial results, highlighting the promising Phase 1 study of botensilimab, an anti-CTLA-4 therapy. The company initiated Phase 2 ACTIVATE trials for botensilimab in advanced colorectal cancer and melanoma. The firm ended Q3 with $218 million in cash and reported a net loss of $56.7 million, or $0.19 per share. Revenue for the quarter was $22.8 million, down significantly from the previous year. Agenus plans to present expanded data at the SITC Annual Meeting on November 12.